Latest Ratios: P/E Ratio -0.8x · EV/EBITDA N/A · ROE -49.5%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $97M | $97M | $215M | $991M | $1.1B | $3.6B | $2.1B | — | — |
| Enterprise Value | $100M | $101M | $224M | $1.0B | $1.1B | $3.6B | $2.1B | — | — |
| P/E Ratio → | -0.81 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 3.19 | — | — | — | — | — | — |
| P/B Ratio | 0.45 | 0.45 | 0.64 | 2.27 | 2.45 | 9.85 | 6.39 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 3.32 | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | — | — | — | — | — | 100.0% |
| Operating Margin | — | — | -283.6% | — | — | — | — | — | -169878.6% |
| Net Profit Margin | — | — | -246.0% | — | — | — | — | — | -150478.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -49.5% | -49.5% | -42.8% | -67.1% | -59.3% | -45.5% | -58.7% | -90.7% | -65.2% |
| ROA | -38.1% | -38.1% | -33.4% | -52.4% | -46.2% | -37.9% | -51.9% | -70.7% | -51.4% |
| ROIC | -40.5% | -40.5% | -35.8% | -50.3% | -43.2% | -51.5% | -62.7% | -650.4% | -249.4% |
| ROCE | -48.5% | -48.5% | -43.9% | -60.5% | -49.1% | -56.6% | -57.9% | -86.6% | -68.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 0.18 | 0.13 | 0.10 | 0.11 | 0.13 | 0.01 | 0.04 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.02 | 0.03 | 0.04 | 0.01 | -0.04 | -0.16 | -0.95 | -0.78 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -91.26 | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.93 | 6.93 | 7.32 | 7.16 | 7.98 | 7.98 | 12.07 | 4.62 | 4.30 |
| Quick Ratio | 6.93 | 6.93 | 7.32 | 7.16 | 7.98 | 7.98 | 12.07 | 4.62 | 4.30 |
| Cash Ratio | 6.73 | 6.73 | 7.04 | 6.96 | 7.72 | 7.74 | 11.84 | 4.51 | 4.05 |
| Asset Turnover | — | — | 0.16 | — | — | — | — | — | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 27.07 | — | — | — | — | — | 23907.50 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $72M | $71M | $65M | $53M | $43M | $41M | $36M | $18M |
Includes 30+ ratios · 8 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ZNTL stock.
Zentalis Pharmaceuticals, Inc.'s current P/E ratio is -0.8x. This places it at the 50th percentile of its historical range.
Zentalis Pharmaceuticals, Inc.'s return on equity (ROE) is -49.5%. The historical average is -59.8%.
Based on historical data, Zentalis Pharmaceuticals, Inc. is trading at a P/E of -0.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Shrinking cash cushion against burn
Metrics are mathematically derived from official filings.
Discount to Book Reflects Impaired Earnings Power
ZNTL trades at a P/B of 0.57 while carrying negative trailing earnings with a P/E of -0.90, so the market is pricing the balance sheet at a steep discount to its stated book value according to reported figures.
A sub-1.0 price-to-book multiple paired with negative earnings indicates the market doubts that book equity will be converted into future cash returns, which is consistent with the reported equity erosion from an accumulated deficit near -$1.3B. Because forward multiples and EV-based metrics are unavailable, valuation cannot be benchmarked against own history or the sector, and peers such as RVMD and PRAX trade at much higher book multiples, which may simply reflect differing pipeline expectations rather than a clear mispricing. Investors should monitor whether the discount narrows as cash burn is funded, since further dilution could compress book value per share further.
Operating Losses Overwhelm Thin Revenue Base
Operating margin deteriorated to roughly -185.6% in 2024Q4 and net margin reached -176.7%, with ROE at -47.6% in 2026Q2, indicating losses far exceed any reported revenue, based on reported figures.
Margin data is sparse after 2024Q4, so the trajectory cannot be fully tracked, but the available readings show expenses running at multiples of revenue rather than a modest gap that scale could close. Relative to the peer group, ZNTL's negative ROE sits in line with clinical-stage peers such as IMVT and PRAX rather than the profitable AUPH and TGTX, suggesting the gap is structural to the pre-commercial model rather than temporary. The more informative measure of earning power for this company is the cash burn rate, since non-cash stock compensation has inflated the reported operating cost base.
Negative Returns Deepen as Capital Base Shrinks
ROIC fell from -4.0% in 2024Q1 to -36.1% in 2026Q2 while ROE moved to -47.6%, reflecting a sustained decay in returns on invested capital, according to the reported quarterly ratios.
The decline in ROIC is driven primarily by a shrinking invested capital base combined with widening losses, rather than by any improvement in capital efficiency, which means returns are being eroded from both the numerator and denominator. Compared with the peer set, ZNTL's ROIC sits well below AUPH and TGTX, which both generate positive returns, and roughly in line with PRAX and KYMR, which are also loss-making. The trend implies the company is currently decaying rather than compounding capital, and investors should monitor whether ROIC stabilizes as burn is reduced.
Elevated Current Ratio Conceals Shrinking Cash Buffer
The current ratio of 4.82 in 2026Q2 appears comfortable, yet cash declined from $41.9M in 2025Q1 to $24.8M, which suggests the liquidity cushion is thinning faster than the ratio implies, based on reported figures.
A current ratio near 5 looks strong in isolation, but it is supported largely by short-term assets that are being consumed by operating burn, so the ratio is declining from its prior 9.19 reading in 2024Q1. Under a severe stress scenario with continued quarterly losses near the reported -$77.6M net loss, the existing cash balance would cover only a fraction of a year of operations, which would warrant further investigation of financing plans. Because the quick ratio matches the current ratio, the company holds essentially no inventory, so liquidity depends entirely on cash and receivables rather than working capital turnover.
Low Leverage Understates Funding Dependence
A debt-to-equity ratio of 0.23 looks conservative, but it likely understates risk because equity is shrinking while the company burns cash, based on reported figures.
The apparent safety of low leverage is largely a function of the shrinking equity denominator, since total debt has stayed near $34M to $45M while equity has fallen, so the D/E increase from 0.10 to 0.23 reflects erosion of the cushion rather than new borrowing. The most commonly misapplied ratio for a clinical-stage biotech is the current ratio, which can appear strong even when the cash runway is short. A more appropriate lens is months of cash runway measured against the quarterly burn rate, which the reported figures suggest is considerably shorter than the balance sheet ratios imply.